InspireMD Commences Trading on Nasdaq-CM

InspireMD, Inc. (Nasdaq-CM: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by Carotid Artery Disease (CAD), today announced that the Company’s shares will commence trading on The Nasdaq Capital Market (“Nasdaq-CM”), today, May 21, 2021, under the symbol NSPR.
 
InspireMD CEO Marvin Slosman said, “The trading of our shares on the Nasdaq Capital Market is a yet another very important step in the continued evolution of InspireMD as we seek to create improved awareness of the Company, broaden our shareholder base, and improve trading liquidity in our efforts to establish a new standard of care in the treatment of carotid artery disease and stroke prevention.”